I work in this area myself as a research scientist and also was a little unimpressed at first.
Their pipeline of viricides are very early stage still in animal models, or earlier, there seems to be some problems with the IP, and I was surprised that such an early stage company was actually publicly traded. Interesting their CSO was in military research before, then going after diseases like Ebola / Dengue - seems they are intending military use as target.
But then I did notice that John Rossi, a very established and capable guy in the field, was on the Scientific Advisory Board. So maybe there is some hope.
Anyway, it's a big gamble this sort of stuff is either worth nothing or might pick up, but going after such a fast-changing target like influenza as their most developed program makes it especially risky even compared to other biotech stocks.